Niwa K, Murase T, Morishita S, Hashimoto M, Itoh N, Tamaya T
Department of Obstetrics and Gynecology, Gifu University School of Medicine, Japan.
Cancer Detect Prev. 1999;23(2):147-54. doi: 10.1046/j.1525-1500.1999.09909.x.
Overexpression and mutation of p53 in 46 primary endometrial carcinomas were determined comparatively with the status for estrogen receptor (ER) and progesterone receptor (PR). Immunohistochemically p53 overexpression was found in 9 of 46 cases (20%), while eight kinds of mutations in that gene were detected in 7 of 46 endometrial carcinomas (15%), using polymerase chain reaction single-strand conformation polymorphism and subsequently direct sequencing method. Six of nine cases with p53 overexpression showed p53 mutation. All eight mutations showed single substitutions, and three cases in exon 4, one in exon 5, two in exon 6, and two in exon 7 were found. The cases with the p53 overexpression were significantly inversely related to that of ER or PR staining. Most endometrial carcinoma with p53 overexpression and/or mutation had a relatively poor prognosis and showed no reactivities of ER or PR.
对46例原发性子宫内膜癌中p53的过表达和突变情况与雌激素受体（ER）和孕激素受体（PR）的状态进行了比较。免疫组织化学检测发现，46例中有9例（20%）存在p53过表达，而采用聚合酶链反应单链构象多态性及随后的直接测序法，在46例子宫内膜癌中有7例（15%）检测到该基因的8种突变。9例p53过表达病例中有6例显示p53突变。所有8种突变均为单碱基替换，其中外显子4中有3例，外显子5中有1例，外显子6中有2例，外显子7中有2例。p53过表达病例与ER或PR染色情况呈显著负相关。大多数伴有p53过表达和/或突变的子宫内膜癌预后相对较差，且ER或PR无反应性。
